Abstract
The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated to cost upwards of US$800 million for each drug to be successfully approved for clinical use. Much of this cost is driven by the late phase clinical trials and therefore the ability to terminate early those projects destined to fail is paramount to prevent unwanted costs and wasted effort. Although neglected diseases drug discovery is driven more by unmet medical need rather than financial considerations, the need to minimise wasted money and resources is even more vital in this under- funded area. To ensure any drug discovery project is addressing the requirements of the patients and health care providers and delivering a benefit over existing therapies, the ideal attributes of a novel drug needs to be pre-defined by a set of criteria called a target product profile. Using a target product profile the drug discovery process, clinical study design, and compound characteristics can be defined all the way back through to the suitability or druggability of the intended biochemical target. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising chances of success.
Keywords: Chemical validation, druggability, drug resistance, genetic validation, neglected diseases, molecular targets, target assessment, target product profile, discovery of drugs, paramount, vital, biochemical target, vector-borne parasitic diseases, African sleeping sickness, molecular target approach
Current Topics in Medicinal Chemistry
Title: Target Validation: Linking Target and Chemical Properties to Desired Product Profile
Volume: 11 Issue: 10
Author(s): Paul G. Wyatt, Ian H. Gilbert, Kevin D. Read and Alan H. Fairlamb
Affiliation:
Keywords: Chemical validation, druggability, drug resistance, genetic validation, neglected diseases, molecular targets, target assessment, target product profile, discovery of drugs, paramount, vital, biochemical target, vector-borne parasitic diseases, African sleeping sickness, molecular target approach
Abstract: The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated to cost upwards of US$800 million for each drug to be successfully approved for clinical use. Much of this cost is driven by the late phase clinical trials and therefore the ability to terminate early those projects destined to fail is paramount to prevent unwanted costs and wasted effort. Although neglected diseases drug discovery is driven more by unmet medical need rather than financial considerations, the need to minimise wasted money and resources is even more vital in this under- funded area. To ensure any drug discovery project is addressing the requirements of the patients and health care providers and delivering a benefit over existing therapies, the ideal attributes of a novel drug needs to be pre-defined by a set of criteria called a target product profile. Using a target product profile the drug discovery process, clinical study design, and compound characteristics can be defined all the way back through to the suitability or druggability of the intended biochemical target. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising chances of success.
Export Options
About this article
Cite this article as:
G. Wyatt Paul, H. Gilbert Ian, D. Read Kevin and H. Fairlamb Alan, Target Validation: Linking Target and Chemical Properties to Desired Product Profile, Current Topics in Medicinal Chemistry 2011; 11 (10) . https://dx.doi.org/10.2174/156802611795429185
DOI https://dx.doi.org/10.2174/156802611795429185 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Battle for Iron between Humans and Microbes
Current Medicinal Chemistry Vaccine Development for Potential Bioterrorism Agents
Current Drug Targets - Infectious Disorders Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis
Current Proteomics Innovative Technologies for Oral Drug Delivery
Current Drug Delivery Relationship Between Carbapenems Structure and Minimal Inhibitory Concentration Selected Bacterial Strains
Letters in Drug Design & Discovery A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Microwave Assisted Preparation of New Dicoumarinyl Pyrazoline Derivatives as Antimicrobials
Current Microwave Chemistry Cost-Effectiveness of Antiretroviral Therapy for Prevention
Current HIV Research Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science Anti-cytokines and Cytokines in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Synthesis and Biological Evaluation of 2-thiazolylimino-5-arylidene-4- thiazolidinone Derivatives as Potent Antimycobacterial Agents
Anti-Infective Agents Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Rifampicin Induced Aggregation of Ovalbumin: Malicious Behaviour of Antibiotics
Protein & Peptide Letters Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Selective Elevation of Circulating CCL2/MCP1 Levels in Patients with Longstanding Post-vaccinal Macrophagic Myofasciitis and ASIA
Current Medicinal Chemistry Toxic Effects of Aflatoxin B1 on Embryonic Development of Zebrafish (Danio rerio): Potential Activity of Piceatannol Encapsulated Chitosan/poly (Lactic Acid) Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury: First Case-Controlled Study from Iran
Current Drug Safety Lipoplexes Formulation and Optimisation: In Vitro Transfection Studies Reveal No Correlation with In Vivo Vaccination Studies
Current Drug Delivery Pleuroscopy Early Experience in the Exudative Pleural Effusion of Unknown Etiology
Current Respiratory Medicine Reviews P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer Therapy
Current Cancer Drug Targets